logo

For the Inventor, By the Inventor

Kreuzlingen, Switzerland

Ekkehard Mössner

USPTO Granted Patents = 15 

 

Average Co-Inventor Count = 2.4

ph-index = 8

Forward Citations = 195(Granted Patents)


Location History:

  • Kreuzlingen, DE (2010)
  • Kreuzlingen, CH (2010 - 2018)

Company Filing History:

goldMedal10 out of 68 
 
Roche Glycart Ag
 patents
silverMedal4 out of 7 
 
Glycart Biotechnology Ag
 patents
bronzeMedal1 out of 3 
 
Roche Glyeart Ag
 patents

Years Active: 2010-2018

Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents
1. 9957326 - Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof (2018-05-01),
2. 9309317 - Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof (2016-04-12),
3. 9296820 - Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function (2016-03-29),
4. 9074008 - Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof (2015-07-07),
5. 9068008 - Antibodies to carcinoembryonic antigen (CEA), methods of making same, and uses thereof (2015-06-30),
6. 8945571 - Targeted immunoconjugates (2015-02-03),
7. 8883980 - Antigen binding molecules with increased Fc receptor binding affinity and effector function (2014-11-11),
8. 8614065 - Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof (2013-12-24),
9. 8273328 - Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof (2012-09-25),
10. 8097436 - Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof (2012-01-17),
11. 8088380 - Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof (2012-01-03),
12. 7846432 - Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof (2010-12-07),
13. 7727741 - Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof (2010-06-01),
14. 7722867 - Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof (2010-05-25),
15. 7662377 - Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof (2010-02-16),

Title: **Inventor Ekkehard Mössner: Pioneering Innovations in Antigen Binding Molecules**

Introduction

Ekkehard Mössner, an accomplished inventor based in Kreuzlingen, Switzerland, is recognized for his significant contributions to the field of biotechnology. With an impressive portfolio of 15 patents, he has made remarkable advancements, particularly in the development of antigen binding molecules, which hold potential therapeutic applications.

Latest Patents

Mössner's latest patents focus on antigen binding molecules (ABMs) that specifically target the epidermal growth factor receptor (EGFR). His inventions encompass recombinant monoclonal antibodies, including chimeric, primatized, and humanized forms that are specific to human EGFR. Furthermore, these patents detail nucleic acid molecules that encode such ABMs, as well as vectors and host cells containing these nucleic acid constructs. A notable aspect of his recent invention is the modification of glycosylation of the ABMs, enhancing their therapeutic properties, such as improved Fc receptor binding and elevated effector function, thereby contributing to innovative treatments for various diseases.

Career Highlights

Throughout his career, Ekkehard Mössner has collaborated with prestigious companies such as Roche Glycart AG and Glycart Biotechnology AG. His work has significantly influenced the field, leading to advancements in monoclonal antibody therapies which are essential for various medical treatments.

Collaborations

Mössner has had the opportunity to work alongside renowned professionals, including Pablo Umaña and Ralf Jörg Hosse. These collaborations have enriched his research and have been instrumental in driving forward the development of cutting-edge biopharmaceutical products.

Conclusion

Ekkehard Mössner exemplifies the innovative spirit of the biotechnology industry through his dedication to research and development. His contributions to the field of antigen binding molecules not only pave the way for new therapeutic solutions but also showcase the importance of collaboration in driving scientific advancements. As Mössner continues to expand his portfolio, the potential impact of his inventions on healthcare remains profound.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…